Clinical Research Directory
Browse clinical research sites, groups, and studies.
DORA and LP in Alzheimer's Disease Biomarkers
Sponsor: Washington University School of Medicine
Summary
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Official title: Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
201
Start Date
2024-03-11
Completion Date
2029-03-11
Last Updated
2025-11-05
Healthy Volunteers
Yes
Conditions
Interventions
Lemborexant 10 mg
Within FDA approved dose 10 mg; capsule; QD, 6 month duration
Lemborexant 20mg
20 mg; capsule; QD; 6 month duration
Placebo
0 mg; capsule; QD; 6 month duration
Locations (1)
Washington University in St. Louis, School of Medicine
St Louis, Missouri, United States